78606-80-1
78606-80-1 結(jié)構(gòu)式
基本信息
(5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE
5(S),6(R),7-TRIHYDROXYHEPTANOIC ACID, METHYL ESTER
Heptanoic acid, 5,6,7-trihydroxy-, methyl ester, (5S,6R)-
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-100450 | BML-111 | 78606-80-1 | 1 mg | 2020元 |
| 2025/02/08 | HY-100450 | (5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE BML-111 | 78606-80-1 | 10 mM * 1 mLin DMSO | 4271元 |
| 2025/02/08 | HY-100450 | (5S,6R)-METHYL 5,6,7-TRIHYDROXYHEPTANOATE BML-111 | 78606-80-1 | 5mg | 5050元 |
常見問題列表
Lipoxin A4 receptor
Angiotensin converting enzyme (ACE)
In H22 cells, BML-111 inhibits the production of vascular endothelial growth factor and reduces hypoxia-inducible factor-1α level.
BML-111 inhibits leukotriene B4-induced cellular migration with an IC
50
of 5 nM.
BML-111 (1 mg/kg; intraperitoneal injection; for 15 days; male Imprinting Control Region mice) treatment suppresses tumor-related angiogenesis and tumor growth in vivo. BML-111 also enhances the in situ apoptosis while inhibiting macrophage infiltration in tumor tissue.
BML-111 protects LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury. BML-111 represses the activity of ACE, but increases the activity of ACE2. BML-111 decreases the expression levels of ACE, AngII, and AngII type 1 receptor (AT1R), meanwhile increases the levels of ACE2, angiotensin-(1-7) (Ang-1-7), and Mas.
| Animal Model: | Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days |
| Result: | Suppressed tumor-related angiogenesis and tumor growth in vivo. |